GuidelineClinical pharmacology and therapeutics2019
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
Open access · hybridAbstract readPractice Guideline
In one paragraph
Guideline in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 3 pooled it
12.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 3 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Vietnamese pharmacogenomic variation in global context: a systematic review and meta-analysis for clinical implementation.Frontiers in pharmacology · 2026Pooled it
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.Clinical pharmacology and therapeutics · 2024Guideline
- Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.Nature communications · 2023Pooled it
- Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial.Clinical and translational science · 2021Trial
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.Clinical pharmacology and therapeutics · 2021Trial
- Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.The pharmacogenomics journal · 2020Trial
- CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.Clinical and translational science · 2019Trial
- Article
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- Pharmacogenomic landscape of a Moroccan cohort: enhancing global diversity and addressing the North African gap.Scientific reports · 2026Article
- The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics-Based Clinical Guidelines.Clinical pharmacology and therapeutics · 2026Article
- The Environmental and Global Impact of Pharmacogenomics: Advancing Green Pharmacy Toward Sustainable and Inclusive Precision Medicine.Journal of personalized medicine · 2026Review
- Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.Clinical and translational science · 2026Article
- CYP2B6 polymorphisms and suicidal behaviour in people living with HIV treated with efavirenz-containing combination antiretroviral therapy: a global case-control study.Frontiers in pharmacology · 2026Article
- Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure.PloS one · 2026Article
- Efavirenz metabolism and CNS toxicity in Ugandan children: impact of CYP2B6 genotype and plasma metabolite profiles.Frontiers in pharmacology · 2026Article
- Opportunities and Challenges of Population Pharmacogenomics.Annals of human genetics · 2025Review
- Expanding biobank pharmacogenomics through machine learning calls of structural variation.Genetics · 2025Article
- Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.Cureus · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 14 institutions in 4 countries.
Zeruesenay DestaDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Roseann S GammalDepartment of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences University School of Pharmacy, Boston, Massachusetts, USA.
Li GongDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
Michelle Whirl-CarrilloDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
Aditya H GaurDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Faculty of Medicine Ramathibodi Hospital, Department of Pathology, Mahidol University, Bangkok, Thailand.
Jennifer HockingsDepartment of Pharmacy and Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Alan MyersDepartment of Diagnostic & Biomedical Sciences, The University of Texas Health Sciences Center School of Dentistry, Houston, Texas, USA.
Marelize SwartDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Rachel F TyndaleCentre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
Collen MasimirembwaAfrican Institute of Biomedical Science & Technology, Wilkins Hospital, Harare, Zimbabwe.
Otito F IwuchukwuDivision of Pharmaceutical Sciences, Fairleigh Dickinson University School of Pharmacy, Florham Park, New Jersey, USA.
Sanika ChirwaDepartment of Internal Medicine, Meharry Medical College School of Medicine, Nashville, Tennessee, USA.
Jeffrey LennoxDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
Andrea GaedigkDivision of Clinical Pharmacology, Toxicology, & Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Teri E KleinDepartment of Biomedical Data Science, Stanford University, Stanford, California, USA.
David W HaasDepartment of Internal Medicine, Meharry Medical College School of Medicine, Nashville, Tennessee, USA.
Stanford University · USMeharry Medical College · USAfrican Institute of Biomedical Science and Technology · ZWCentre for Addiction and Mental Health · CAChildren's Mercy Hospital · USCleveland Clinic · USEmory University · USFairleigh Dickinson University · USIndiana University – Purdue University Indianapolis · USIndiana University School of MedicineMCPHS University · USRamathibodi Hospital · THSt. Jude Children's Research Hospital · USThe University of Texas Health Science Center at Houston · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MThe RCMI Program in Health Disparities Research at Meharry Medical College - SupplementU54MD007586 · NIMHD · MEHARRY MEDICAL COLLEGE · PI Samuel Evans Adunyah, JAMES E HILDRETH · 2017 to 2026
$48.2MLC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2MVanderbilt HIV Clinical Trials Unit (CTU)UM1AI069439 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David W Haas, Spyros A Kalams · 2012 to 2026
$33.1MTennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Stephany Norah Duda · 2015 to 2026
$27.5MPharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2MTechnologies and Resources CoreU54MD007593 · NIMHD · MEHARRY MEDICAL COLLEGE · PI ADUNYAH, SAMUEL EVANS · 2012 to 2018
$24.7MPharmacogenomics of HIV TherapyR01AI077505 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HAAS, DAVID W · 2008 to 2025
$12.3MClinical Pharmacogenetics Implementation Consortium (CPIC)U24HG010135 · NHGRI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CAUDLE, KELLY E., KLEIN, TERI ELLEN · 2018 to 2022
$5.4MEmbedding Pharmacogenotyping in an Integrated Health System for the UnderservedU01HG007762 · NHGRI · INDIANA UNIVERSITY INDIANAPOLIS · PI DEXTER, PAUL, SKAAR, TODD C. · 2014 to 2018
$4.4MClinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6MCIHR FDN-154294NCATS NIH HHS UL1 TR002243NHGRI NIH HHS U01 HG007762NHGRI NIH HHS U24 HG010135NIAID NIH HHS P30 AI110527NIAID NIH HHS R01 AI077505NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716NIGMS NIH HHS R01 GM078501NIGMS NIH HHS R01 GM121707NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS R24 GM123930NIGMS NIH HHS R35 GM131812NIMHD NIH HHS U54 MD007586NIMHD NIH HHS U54 MD007593
Abstract
The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.
Indexed as
HIV-1HIV InfectionsAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesCytochrome P-450 CYP2B6HumansPharmacogeneticsPharmacogenomic TestingAlkynesAnti-HIV AgentsBenzoxazinesCyclopropanesCYP2B6 protein, humanCytochrome P-450 CYP2B6efavirenz
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.